Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-08T00:37:02.726Z Has data issue: false hasContentIssue false
  • English
  • Français

An essay on the use of new antipsychotics

Published online by Cambridge University Press:  02 January 2018

Robert W. Kerwin
Robert W. Kerwin*
Affiliation:
Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In a textbook of psychopharmacology published as recently as 1990, Hollister and Csernansky wrote about antipsychotics “It is most discouraging that more effective pharmacotherapy has not been developed. Present drugs have many deficiences: they are not curative; their ameliorative effects are often limited, many patients remain totally unresponsive; they are unpleasant to take so that many patients are less than fully compliant; they produce major side effects such as tardive dyskinesia whose full implications are still uncertain”.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 20 , Issue 1 , January 1996 , pp. 23 - 26
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1996

References

Aitchison, K. J. & Kerwin, R. W. (1994) The costs and benefits of clozapine therapy in the UK (Abstract). Schizophrenia Research, 15, 141.CrossRefGoogle Scholar
Aubree, J. C. & Lader, M. H. (1980) High and very high dose antipsychotics: a critical review. Journal of Clinical Psychiatry, 41, 341–356.Google ScholarPubMed
Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic doses and plasma levels in the pharmacological management of the psychoses. Archives of General Psychiatry, 46, 79–91.Google Scholar
Buchanan, A. (1992) A two year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine, 22, 787–789.CrossRefGoogle ScholarPubMed
Claghorn, J., Honigfeld, G., Abuzzahab, S. S., et al (1987) The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377–384.Google Scholar
Frances, A. J. & Weiden, P. (1987) Promoting compliance with outpatient drug treatment Hospital and Community Psychiatry, 38, 1158–1160.Google Scholar
Hale, A. (1993) Will the new antipsychotics improve the treatment of schizophrenia. British Medical Journal 307, 749–750.Google Scholar
Hollister, L. E. & Csernansky, J. G. (1990) Clinical Pharmacology of Psychotherapeutic Drugs (3rd edn). New York: Churchill Livingstone.Google Scholar
Jasik, N. & Lader, M. (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry, 165, 787–791.Google Scholar
Johnstone, E. C., et al (1993) Schizophrenia: problems in clinical practice. Lancet, 341, 536–538.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (Clozaril Collaborative Study Group) (1988) Clozapine for the treatment resistant schizophrenic: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
King, D. J. & Mills, P. (1993) Clozapine: the Holywell experience with the first 24 patients. Irish Journal of Psychological Medicine, 10, 30–34.CrossRefGoogle Scholar
Marder, S. R. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.Google Scholar
Matheson, L. A., Cook, H. M., McKenna, P. J., et al (1993) Purchasing Care for Patients with Schizophrenia. Health Policy Unit review No 5. England: Daniels Publishing.Google Scholar
Meltzer, H. Y. & Cola, P. A. (1994) The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry, 55 (Suppl. B), 161–165.Google ScholarPubMed
Meltzer, H. Y. & Cola, P. A. Cola, P., Way, L., et al (1993) Cost-effectiveness of clozapine in neuroleptic resistant schizophrenia. American Journal of Psychiatry, 150, 1630–1638.Google Scholar
Pilowsky, L. S., Costa, D. C., Murray, R. M., et al (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I-IBZM SPET (single photon emission tomography) study. Psychological Medicine, 23, 791–797.CrossRefGoogle ScholarPubMed
Reid, W. H., Mason, M. & Topral, M. (1994) Savings in hospital bed days related to treatment with clozapine. Hospital and Community Psychiatry, 45, 261–264.Google Scholar
Reid, W. H., Mason, M. & Topral, M. (1994) The treatment of psychosis: resetting the drug cost thermostat. Journal of Clinical Psychiatry, 55 (Suppl. B). 166–168.Google ScholarPubMed
Revicki, D. A., Luce, B. R., Wexhler, J. M., et al (1990) Cost-effectiveness of clozapine for treatment resistant schizophrenic patients. Hospital and Community Psychiatry, 41, 850–854.Google Scholar
Rifkind, A., Doddi, S., Karagiagi, B., et al (1991) Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166–170.CrossRefGoogle Scholar
Shaikh, S., Collier, D., Kerwin, R. W., et al (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet, 341, 116.CrossRefGoogle ScholarPubMed
Thomson, C. (1994) The use of high-dose antipsychotic medication (Consensus Statement). British Journal of Psychiatry, 164, 448–458.Google Scholar
Vincent, P. C. (1986) Drug induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs, 31, 52–63.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.